- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Aug 1, 2020
Product Development
July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck
BioCentury | Apr 29, 2020
Product Development
Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities
BioCentury | Feb 14, 2020
Finance
You say you want a Revolution? Oncology company is latest to post big gain after IPO
BioCentury | Jul 9, 2019
Finance
Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos
How Revolution Medicines plans to deploy Boxer Capital-led series C to advance portfolio of Ras pathway inhibitors
BioCentury | Jun 28, 2019
Product Development
How Array stayed alive long enough to grow up
Array's strategic toggle between R and D enabled the platform company's 21 year lifespan and $11.4 billion takeout.
BioCentury | Jun 22, 2019
Clinical News
June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell
BioCentury | Jun 20, 2019
Targets & Mechanisms
Moving beyond the active site: why allostery is newly in fashion
How a new class of biotechs is turning allostery from serendipitous to systematic
BioCentury | Jun 17, 2019
Company News
Array takeout buoys biotechs, strengthens Pfizer in targeted oncology
BioCentury | May 10, 2019
Product Development
Exelixis to fuel pipeline growth with Cabometyx cash flows
How Exelixis plans to parlay Cabometyx sales into internal R&D and late-stage deals to expand its pipeline
Items per page:
1 - 10 of 42